Author

admin

Browsing

Investor Insight Cardiol Therapeutics is positioned with a late-stage lead asset, multiple orphan indications, strong clinical proof-of-concept data, and a differentiated non-immunosuppressive approach to inflammatory heart disease. The company’s 2025–2026 catalysts – MAVERIC Phase III enrollment progress, full ARCHER data, and CRD-38 clinical initiation – are key value drivers in…

Bold Ventures Inc. (TSXV: BOL,OTC:BVLDF) (the ‘Company’ or ‘Bold’) is pleased to announce the results of a prospecting and sampling program on its Burchell Gold and Copper Property (the ‘Property’), located within the Shebandowan Greenstone Belt, approximately 100 km west of Thunder Bay, Ontario. 209 grab samples and 42 channel…